An integrative data mining approach to identifying adverse outcome pathway signatures

Toxicology

Volumn 350-352, Issue , 2016, Pages 49-61

  Oki, Noffisat O ^a   Edwards, Stephen W ^b  

^a OAK RIDGE INSTITUTE FOR SCIENCE AND EDUCATION   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Adverse outcome pathway (AOP); CpAOP; Glaucoma; Steatosis

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR;

ADVERSE OUTCOME; ADVERSEO OUTCOME PATHWAY FRAMEWORK; ARTICLE; BIOLOGY; DATA MINING; FATTY LIVER; GENE EXPRESSION; GENE MAPPING; GENE TARGETING; GENETIC ASSOCIATION; GLAUCOMA; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PHENOTYPE; PRIORITY JOURNAL; ANIMAL; FACTUAL DATABASE; GENETICS; PROCEDURES; TOXICOGENETICS;

ANIMALS; DATA MINING; DATABASES, FACTUAL; FATTY LIVER; GENE EXPRESSION; GLAUCOMA; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; RECEPTORS, ARYL HYDROCARBON; TOXICOGENETICS;

EID: 84968813304     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2016.04.004     Document Type: Article

References (57)

1. Agrawal R., Srikant R. Fast algorithms for mining association rules in large databases. Proceedings of the 20th International Conference on Very Large Data Bases 1994, 487-499. Morgan Kaufmann Publishers Inc.
2. Agrawal R., et al. Mining association rules between sets of items in large databases. SIGMOD Rec. 1993, 22(2):207-216.
3. Alexander D.L., et al. Aryl-hydrocarbon receptor is an inhibitory regulator of lipid synthesis and of commitment to adipogenesis. J. Cell Sci. 1998, 111(22):3311-3322.
4. Angrish M.M., et al. Tipping the balance: hepatotoxicity and the four apical key events of hepatic steatosis. Toxicol. Sci. 2016, 150(2):261-268.
5. Ankley G.T., et al. Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ. Toxicol. Chem. 2010, 29(3):730-741.
6. Attene-Ramos M.S., et al. The Tox21 robotic platform for the assessment of environmental chemicals-from vision to reality. Drug Discovery Today 2013, 18(15-16):716-723.
7. Bai L., et al. Transcription coactivator mediator subunit Med1 is required for the development of fatty liver in the mouse. Hepatology (Baltimore Md.) 2011, 53(4):1164-1174.
8. Beischlag T.V., et al. The aryl hydrocarbon receptor complex and the control of gene expression. Crit. Rev. Eukaryotic Gene Expr. 2008, 18(3):207-250.
9. Bell S.M., Edwards S.W. Building associations between markers of environmental stressors and adverse human health impacts using frequent itemset mining. Proceedings of the 2014 SIAM International Conference on Data Mining 2014, 551-559.
10. Bell S.M., Edwards S.W. Identification and prioritization of relationships between environmental stressors and adverse human health impacts. Environ. Health Perspect. 2015, 123:1193-1199.
11. Bell S., et al. Integrating publicly-available data to generate computationally-predicted adverse outcome pathways for fatty liver. Toxicol. Sci. 2016, 150(2):510-520.
12. Borgelt C. Frequent item set mining. Wiley Interdiscip. Rev. Data Min. Knowl. Discovery 2012, 2(6):437-456.
13. Brake P.B., Zhang L., Jefcoate C.R. Aryl hydrocarbon receptor regulation of cytochrome P4501B1 in rat mammary fibroblasts: evidence for transcriptional repression by glucocorticoids. Mol. Pharmacol. 1998, 54(5):825-833.
14. R Core Team, R: A language and environment for statistical computing. Vienna, Austria; 2014. URL , 2015. http://www.R-project.org.
15. Croft D., et al. The reactome pathway knowledgebase. Nucleic Acids Res. 2014, 42(Database issue):D472-D477.
16. Davis A.P., et al. The comparative toxicogenomics database's 10th year anniversary: update 2015. Nucleic Acids Res. 2015, 43(Database issue):D914-D920.
17. Desvergne B., Wahli W. Peroxisome Proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 1999, 20(5):649-688.
18. Hahsler M., Grün B., Hornik K. A computational environment for mining association rules and frequent item sets. Institut für Statistik und Mathematik 2005, WU Vienna University of Economics and Business, Vienna.
19. Hao N., Whitelaw M.L. The emerging roles of AhR in physiology and immunity. Biochem. Pharmacol. 2013, 86(5):561-570.
20. Hardwick J.P., et al. PPAR/RXR regulation of fatty acid metabolism and fatty acid ω-hydroxylase (CYP4) isozymes: implications for prevention of lipotoxicity in fatty liver disease. PPAR Res. 2009.
21. Hewitt K.N., et al. Estrogen replacement reverses the hepatic steatosis phenotype in the male aromatase knockout mouse. Endocrinology 2004, 145(4):1842-1848.
22. Hu B., et al. Analysis of the ToxCast chemical-assay space using the comparative toxicogenomics database. Chem. Res. Toxicol. 2015, 28(11):2210-2223.
23. Huang D.W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2008, 4(1):44-57.
24. Huang D.W., Sherman B.T., Lempicki R.A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009, 37(1):1-13.
25. Jacob A., et al. Aryl hydrocarbon receptor-dependent upregulation of Cyp1b1 by TCDD and diesel exhaust particles in rat brain microvessels. Fluids Barriers CNS 2011, 8. 23-23.
26. Jacob A., et al. Aryl hydrocarbon receptor regulates CYP1B1 but not ABCB1 and ABCG2 in hCMEC/D3 human cerebral microvascular endothelial cells after TCDD exposure. Brain Res. 2015, 1613:27-36.
27. Judson R.S., et al. In vitro screening of environmental chemicals for targeted testing prioritization: the ToxCast project. Environ. Health Perspect. 2010, 118(4):485-492.
28. Kanehisa M., et al. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res. 2014, 42(Database issue):D199-D205.
29. Lee S.S., et al. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 1995, 15(6):3012-3022.
30. Mascanfroni I.D., et al. Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-[alpha]. Nat. Med. 2015, 21(6):638-646.
31. Messina-Baas O.M., et al. Molecular analysis of the CYP1B1 gene: identification of novel truncating mutations in patients with primary congenital glaucoma. Ophthal. Res. 2007, 39(1):17-23.
32. Milacic M., et al. Annotating cancer variants and anti-cancer therapeutics in reactome. Cancers 2012, 4(4):1180-1211.
33. Morán-Salvador E., et al. Role for PPARγ in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. FASEB J. 2011, 25(8):2538-2550.
34. Motojima K., et al. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor α and γ activators in a tissue- and inducer-specific manner. J. Biol. Chem. 1998, 273(27):16710-16714.
35. Nakajima T., et al. Peroxisome proliferator-activated receptor α protects against alcohol-induced liver damage. Hepatology 2004, 40(4):972-980.
36. Nebert D.W., et al. Role of Aryl Hydrocarbon Receptor-mediated Induction of the CYP1 enzymes in environmental toxicity and cancer. J. Biol. Chem. 2004, 279(23):23847-23850.
37. Nguyen N.T., et al. The roles of aryl hydrocarbon receptor in immune responses. Int. Immunol. 2013, 25(6):335-343.
38. Pawlak M., Lefebvre P., Staels B. Molecular mechanism of PPARα action and its impact on lipid metabolism: inflammation and fibrosis in non-alcoholic fatty liver disease. J. Hepatol. 2015, 62(3):720-733.
39. Peng C.-Y.J., et al. Advances in missing data methods and implications for educational research. Real Data Anal. 2016, 2006:31-78.
40. Peters J.M., Cattley R.C., Gonzalez F.J. Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis 1997, 18(11):2029-2033.
41. Pyper S.R., et al. PPARα: energy combustion, hypolipidemia, inflammation and cancer. Nucl. Recept. Signaling 2010, 8:e002.
42. Quintana F.J., et al. Control of treg and TH17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008, 453(7191):65-71.
43. Rao S.M., Reddy J.K. PPARα in the pathogenesis of fatty liver disease. Hepatology 2004, 40(4):783-786.
44. Reddy J.K., Sambasiva Rao M. Lipid Metabolism and Liver Inflammation. II. Fatty liver disease and fatty acid oxidation. Am. J. Physiol. 2006, 290(5):G852-G858.
45. Reddy J.K. Peroxisome proliferators and peroxisome proliferator-activated receptor α: biotic and xenobiotic sensing. Am. J. Pathol. 2004, 164(6):2305-2321.
46. Seo Y.S., et al. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. J. Gastroenterol. Hepatol. 2008, 23(1):102-109.
47. Shannon P., et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003, 13(11):2498-2504.
48. Shehin S.E., Stephenson R.O., Greenlee W.F. Transcriptional regulation of the human CYP1B1 gene: evidence for involvement of an aryl hydrocarbon receptor response element in constitutive expression. J. Biol. Chem. 2000, 275(10):6770-6776.
49. Stockinger B., et al. The aryl hydrocarbon receptor: multitasking in the immune system. Ann. Rev. Immunol. 2014, 32(1):403-432.
50. Stoilov I., Akarsu A.N., Sarfarazi M. Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. Hum. Mol. Genet. 1997, 6(4):641-647.
51. Tsuchiya Y., Nakajima M., Yokoi T. Critical enhancer region to which AhR/ARNT and Sp1 bind in the human CYP1B1 gene. J. Biochem. 2003, 133(5):583-592.
52. Vasiliou V., Gonzalez F.J. Role of CYP1B1 in glaucoma. Ann. Rev. Pharmacol. Toxicol. 2008, 48(1):333-358.
53. Viswakarma N., et al. Coactivators in PPAR-regulated gene expression. PPAR Res. 2010, 2010:21.
54. Volotinen M., et al. Expression of cytochrome P450 (CYP) enzymes in human nonpigmented ciliary epithelial cells: induction of CYP1B1 expression by TCDD. Invest. Ophthalmol. Visual Sci. 2009, 50(7):3099-3105.
55. Yang X., et al. Constitutive regulation of CYP1B1 by the aryl hydrocarbon receptor (AhR) in pre-malignant and malignant mammary tissue. J. Cell. Biochem. 2008, 104(2):402-417.
56. Yu S., et al. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor γ1 (PPARγ1) overexpression. J. Biol. Chem. 2003, 278(1):498-505.
57. Zhang H., et al. Differential effects of estrogen/androgen on the prevention of nonalcoholic fatty liver disease in male rat. J. Lipid Res. 2013, 54(2):345-357.